Stay Tuned: ASCO 2010 is Just Around the Corner

Article

The theme of this year’s ASCO meeting is “advancing quality through innovation.” As always, the vast scope of this annual meeting is daunting. In order to give our readers an ongoing analysis of ASCO ’10, The Oncology Forum will be posting daily from Chicago, parsing out the best sessions and most relevant clinical information.

The theme of this year’s annual  ASCO meeting is “advancing quality through innovation.” As always, the vast scope of this international meeting is daunting. In order to give our readers an ongoing analysis of ASCO ’10, The Oncology Forum will be posting daily from Chicago, parsing out the best sessions and most relevant clinical information. 

The Forum will also highlight the most important practice management information, nuts & bolts tips that will help your practice’s bottom line and analysis of how Obama’s healthcare bill will impact the ability to treat your patients in the brave new world of comparative effectiveness research (CER) and steep Medicare cuts.


Here’s a new feature from this year’s meeting:

Trials in Progress Poster Session
 

The new Trials in Progress Poster Session will facilitate awareness of and dialogue about open, ongoing clinical trials. It differs from other Poster Sessions in that:

--outcomes data or results are not included,

--the goal is to promote discussion among trial investigators, to encourage recruitment of new investigators or sites, and to stimulate discussion of successor or confirmatory trials, 

--the focus is on the background of the science behind the trial, and preclinical or earlier-phase data (preferably with references) is encouraged.
 

Also, watch The Forum for exclusive interviews from the meeting's top presenters.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Improving data collection and biomarker development across institutions may represent areas of expansion in kidney cancer research.
KIM-1 is a biomarker in the blood that may help noninvasively detect kidney cancer, according to Wenxin (Vincent) Xu, MD.
A phase 0 trial is seeking to assess the feasibility of aiding anti-cancer cells with cytokines to restore their function.
Although pembrolizumab addressed a long-standing need in adjuvant kidney cancer treatment, combinations with the agent may further bolster efficacy.
“The trial will be successful, or [we’ll] declare it a success if we see at least 3 of 24 responses overall,” stated Ravi, MD, BChir, MRCP, on the phase 2 LASER trial in RCC.
Success with the 177Lu-PSMA-617 radioligand therapy would be transformative for the clear cell renal cell carcinoma treatment landscape.
5 experts are featured in this series
4 experts in this video
Related Content